Introduction
The world population is aging at a rapid rate, in high-and low-income countries, challenging health care services from both the organizational and the economic point of view. Throughout the world, the number of people over 60 years doubled in the last century and in Europe, for example, the share of older population is expected to peak at up to 30% by 2050. 1 Such epidemiological transition drives the pressing
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lucenteforte et al burden of the increasing prevalence of chronic diseases in this age group. 2 In addition to the complexities related to the clinical management of older people suffering from multiple chronic diseases, one of the challenges physicians are facing is the consequent complication of complex pharmacological regimens.
Even if the potential benefits of pharmacological therapy are unquestionable, the hazards of negative drug-related outcomes often raise relevant concerns in older adults. Polypharmacy increases the risk of drug-drug and drug-disease interactions, and age-related changes in several physiological characteristics, as well as the presence of chronic illnesses (eg, chronic kidney or liver disease), may affect drugs' pharmacokinetics and pharmacodynamics. Such issues potentially increase the risk of adverse drug reactions (ADRs) and explain the significant excess of morbidity, mortality rate, and health care costs within the older population.
In this context, what constitutes an appropriate or inappropriate prescription (IP) in the context of the geriatric population is still debated. Indeed, in order to identify inappropriate pharmacological prescriptions, different criteria have been proposed in recent years. The best known are the Beers criteria, 3 the Screening Tool of Older People's Prescriptions (STOPP), Screening Tool to Alert to Right Treatment (START), 4 as well as the Medication Appropriateness Index (MAI), 5 and the Assessing Care of Vulnerable Elderly (ACOVE) 6 criteria. These criteria and tools are based on expert consensus and are not specifically tailored to any particular disease, even though stroke, myocardial infarction (MI), and other cardiovascular disorders constitute the most frequently treated clinical conditions by physicians in Western countries. Moreover, their impact has not been exhaustively validated toward "hard" end points, and they do not comprise an accurate selection and validation process of drug-drug interactions in light of overlying comorbidities.
Thus, the definition of IP indicators for older adults affected by cardiovascular disease and chronic comorbidities could be extremely useful for the prescriber and might offer advantages from a public health perspective. The aim of the present review was to identify and suggest to the scientific community a list of potential indicators for older adults suffering from cardiovascular diseases and other chronic comorbidities, to be subsequently validated in an ad hoc selected population sample, and eventually proposed as IP indicators. More specifically, we identified all the studies reporting a suspect of drug-related harm in the context of multimorbid older adults suffering from cardiovascular diseases and clustered them according to homogenous groups. Cardiovascular diseases are defined according to the World Health Organization as a group of disorders of the heart and blood vessels and include coronary heart disease, cerebrovascular disease, peripheral arterial disease, rheumatic heart disease, congenital heart disease, and deep vein thrombosis and pulmonary embolism. 60 
Methods
We performed this systematic review in keeping with the Cochrane Handbook for Systematic Reviews and reported the results according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). The protocol was registered a priori on PROSPERO (N CRD42017057795).
Data source and search strategy
We conducted a systematic search of PubMed, EMBASE, and CENTRAL databases up to October 2, 2014. A librarian (ZM) structured the search on free text and MESH terms with regard to four different domains: "prescriptions", "adverse events", "cardiovascular conditions", and "older people".
The The same investigators independently reviewed full texts and selected articles addressing inappropriate prescribing in elderly patients affected by cardiovascular condition using the following inclusion criteria: 1. Studies on people aged $65 years 2. Studies on patients with no restriction of age but with data on subjects aged $65 years 3. Observational effectiveness studies.
We resolved disagreement by discussion and consensus with a third trained assessor (DLC). Additionally, we reviewed the reference lists of the included studies and previous reviews to identify additional papers that met inclusion criteria.
Data extraction and quality assessment
For each selected study, we extracted the following data: year of publication, study design, drugs, outcomes, country and setting, characteristic of the study population (eg, sample size, age, and gender), information on follow-up, and main results (ie., estimated with corresponding confidence intervals for each outcome) and additional results.
Two investigators (NL and DLC) independently assessed the methodological quality of included studies using the Newcastle-Ottawa Scale (NOS) 7 for case-control and cohort study, the scale proposed by Jadad et al for randomized controlled trials, 8 and the following criteria for case-crossover studies and self-controlled case series: 1. Clearly stated aims 2. Appropriate methods are used 3. Well constituted context of the study 4. Clearly described, valid, and reliable results 5. Clearly described analysis 6. Possible influences of the outcome are considered 7. Conclusion is linked to the aim, analysis, and interpretation of results of the study 8. Limitations on research are identified.
Results
The PRISMA flow diagram of study selection is shown in Figure 1 . The database search produced 5,742 citations. After removal of duplicates, we reviewed titles and abstracts of 3880 records, among which 374 met the inclusion criteria and the corresponding full texts were retrieved and reviewed. Subsequently, 325 studies were removed because they did not present analysis for patients aged $65 years (258 papers) and had inappropriate study design (50) , or for other reasons (6 were not original studies, 4 were on patients without cardiovascular disease, 2 with no safety outcomes, 2 with efficacy outcomes only, 2 were duplicate publications, and 1 was on exposure other than drug).
Supplementary material reports the characteristics of the 49 selected studies grouped according to 32 homogeneous potential IP indicators. Briefly, among the selected studies, Studies had a good quality (NOS: 9 or 8/9, quality assessment: 7 or 8/8, Jadad: 4/5) in 14 out of 49 cases (29%), moderate (NOS: 7 or 6/9) in 30 cases (61%), and low (NOS: ,6/9) in 5 cases (10%).
Discussion
The present systematic review led to the selection of 32 groups of studies indicating potential drug-related harm in older people with cardiovascular diseases. Among them, only 19 included at least one study that showed significant and direct association with adverse events, triggering a potential warning for a specific drug or class of drugs in a specific context. According to the authors of the present review, these 19 groups can be deemed as potential indicators of IP in multimorbid older adults affected by cardiovascular diseases.
The optimization of pharmacological therapy is an essential part of the process of care for an older person. In the past 20 years, several expert panels in Canada, the USA, and Europe have developed different sets of criteria useful 
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Inappropriate pharmacological treatment in older cardiovascular adults for making quality assessments of prescribing practices and medication use in older adults and potentially helpful during the process of medication review. The most widely used criteria for inappropriate medications are the Beers criteria, 3 initially developed in 1991 in the USA to target nursing home residents and then revised in 1997, 2003, 2012, and most recently in 2015. These criteria include more than 50 medications assigned to one of three possible categories: those that should always be avoided, those that are potentially inappropriate in older adults with particular health conditions or syndromes, and those that should be used with caution. It has been shown that potentially inappropriate medications included in the Beers criteria are associated with poor health outcomes such as confusion, falls, and mortality. Another important set of criteria is represented by START/STOPP 4 which were first published in 2008 and last updated in 2014. STOPP criteria identify prescriptions that are potentially inappropriate to use in patients aged $65 years, while START criteria list drug therapies that should be considered where no contraindication to prescription exists in the same group of patients. Beers and START/STOPP criteria overlap in several areas, making them able to predict ADRs, but often with different reliability. 58, 59 The list of indicators provided in the present review is intended as a set of potential indicators of IP that need to be tested in the real world through a validation process based on tailored studies to explore health outcomes in different older populations and across different care settings. Eventually, these validation studies might lead to a structural proposal for a new set of criteria of IP in older adults suffering from multiple chronic conditions and affected by cardiovascular diseases. This systematic review represents the first step in the process of validation of new indicators, granted by the Italian Medicine Agency (AIFA) and carried out by the I-GrADE consortium.
Our list of potential indicators partially overlaps those proposed by the Beers and STOPP criteria. Several drugs highlighted in this review, including anticoagulants, antiplatelet, blood pressure lowering medications, and many psychotropic drugs, are listed by at least one of the aforementioned criteria. However, this can be no more than an indirect comparison, considering that this review specifically focuses on multimorbid older people suffering from cardiovascular diseases. However, when the attention of such criteria is focused on specific conditions, the agreement intensifies. For example, Beers criteria include a section of recommendations valid in specific contexts and make the case of HF. They point out NSAIDs, CCBs, thiazolidinediones, cilostazol, and dronedarone as potentially inappropriate medications in older adults suffering from HF. Interestingly, three out of five of these drugs have been included in our list. Several selection criteria beyond the specific selection of a population affected by cardiovascular diseases, and the decision-making process itself, might explain these and other discrepancies.
Several drugs not recommended for the treatment of cardiovascular diseases (but that have a potential role in determining ADRs in people with heart diseases) have been included in our list. Some of them are proposed here for the first time as potentially inappropriate. For example, in the study from Abrahamsen et al 10 bisphosphonates showed a possible correlation with AF in patients with an underling cardiac disease. This finding, considering the high prevalence of both osteoporosis and cardiovascular diseases in the older population, represents an interesting area of future research, especially when considering the broad set of bisphosphonates with different pharmacokinetics and pharmacodynamics and the actual possibility of replacing these drugs with compounds recently developed for the treatment of osteoporosis, with a more favorable safety profile and good tolerance.
On the other hand, our research underlines the potential harm linked to drugs that have been synthesized and are recommended for the treatment of cardiovascular diseases. This is the case of statins whose toxicity, according to a research published in 2013 by Patel et al, 40 may be exacerbated when co-prescripted with macrolides (especially clarithromycin and erythromycin). Considering the high frequency of use of both classes of drugs related to the prevalence of cardiovascular diseases in elders and the presence of macrolides in first-line therapy of communityacquired pneumonia -which is in turn a main cause of hospitalization in patients over 65 -it is very important to clarify the possible effect of such a co-prescription. In fact, the natural decline in renal function that accompanies aging may exaggerate the consequences of a rhabdomyolysis with a dramatic increase in the frequency of acute kidney failure and an excess of mortality.
As in the most recent 2015 version of Beers criteria, we took into account some drug-disease or drug-syndrome interactions. Some of them are well known and have been extensively explored in the literature, as is the case for antipsychotics and dementia, while others are completely new (ie., antidiabetics and stage renal disease or disability), thus opening the way to new and interesting knowledge acquisitions or future research areas.
To our knowledge, the present work is the first time a systematic review of studies has reported any kind of association between drug use and ADRs in multimorbid older adults suffering from cardiovascular diseases. However, the results we report should be read keeping in mind some limitations. First, we did not include any study assessing under use of medications, and it is now clear that underprescribing appropriate medications can be as great a concern as is overprescribing. Prescribing strategies that seek to simply limit the overall number of drugs prescribed to older adults in the name of improving quality of care may be seriously misdirected. Second, considering the broad and complex spectrum of scenarios existing when it comes to multimorbid older adults, and the heterogeneity of studies present in the literature, our search strategy might have missed some relevant hits. However, bibliographies of the selected papers were scrutinized in an attempt to reduce such occurrence. Third, the heterogeneity of study methodologies and care settings precludes the direct translation of our findings in definitive criteria of IP. However, this was an a priori assumption that suggests the setting up and running of ad hoc studies aimed at validating the criteria suggested here. Finally, a judgment of appropriateness cannot be issued on the basis of an all-or-nothing principle, but we should consider dose-dependent appropriateness of every drug for every target population. In this regard, none of the possible indicators relates to drug dosage, and we know that drug doses can be a main determinant for adverse drug events. Moreover, older patients often present an increased volume of distribution and a decreased drug clearance, which can prolong drug half-lives and lead to increased plasma drug concentrations. In addition, a decline in hepatic function with advancing age may account for significant variability in drug metabolism among older adults.
Other limitations were the exclusion of studies published in languages other than English and a lack of risk-of-bias assessment while quality of reporting was assumed to be directly related to quality of information.
Conclusion
The correct clinical and pharmacological management of complex older adults requires the availability of reliable tools of risk stratification, outcome prediction, and appropriateness of care. According to the present systematic review, both cardiovascular and non-cardiovascular drugs increase the risk of ADRs in older adults with cardiovascular diseases. As part of the I-GrADE consortium, the authors of the present study propose a list of potential indicators of IP for application in the context of multimorbid older adults suffering from cardiovascular diseases. It is worth passing such potential indicators through a validation process carried out in the real-world older population and across different care settings. This is part of the commitment of I-GrADE, and such a process will eventually lead to the publication of a reliable list of indicators of IP tailored to the aforementioned population. This and other efforts by the scientific community are required in the near future in order to cope with the emergency that stems from the rapid aging of the world population and to eventually provide better and more sustainable care to older adults.
